Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Oaknin

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 27, 2007
Update in the management of ovarian and cervical carcinomaA Poveda, R Salazar, J M del Campo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2022
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upA Oaknin, T J Bosse, C L Creutzberg, et al.
Cancer Chemotherapy and Pharmacology|August 29, 2012
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumorsR Salazar, R J Jones, A Oaknin, et al.
ESMO Open|July 30, 2021
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)J A Perez-Fidalgo, A Cortés, E Guerra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)K Fujiwara, B J Monk, C Lhommé, et al.
Gynecologic Oncology|January 22, 2022
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysisA Poveda, S Lheureux, N Colombo, et al.
Gynecologic Oncology|December 16, 2018
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patientsV Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 2024
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trialA Alvarez Secord, S N Lewin, C G Murphy, et al.
Gynecologic Oncology|November 21, 2019
Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277]V Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 27, 2007
Update in the management of ovarian and cervical carcinomaA Poveda, R Salazar, J M del Campo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2022
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upA Oaknin, T J Bosse, C L Creutzberg, et al.
Cancer Chemotherapy and Pharmacology|August 29, 2012
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumorsR Salazar, R J Jones, A Oaknin, et al.
ESMO Open|July 30, 2021
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)J A Perez-Fidalgo, A Cortés, E Guerra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)K Fujiwara, B J Monk, C Lhommé, et al.
Gynecologic Oncology|January 22, 2022
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysisA Poveda, S Lheureux, N Colombo, et al.
Gynecologic Oncology|December 16, 2018
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patientsV Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 2024
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trialA Alvarez Secord, S N Lewin, C G Murphy, et al.
Gynecologic Oncology|November 21, 2019
Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277]V Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Pageof 3